Synosia Reworks Roche Deal To Take On Alzheimer’s/Schizophrenia Candidate
This article was originally published in The Pink Sheet Daily
Executive Summary
Privately held Swiss biotech thinks 5-HT6 antagonists could offer superior targeting and side-effect profiles.